Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1975;45:302-304
© 1975 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WOOD, G. P.
Right arrow Articles by MIKHAIL, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WOOD, G. P.
Right arrow Articles by MIKHAIL, G.

Hormonal Changes Associated with Danazol Therapy

GARY P. WOOD, MD, FACOG, CHUNG-HSIU WU, MD, GEORGE L. FLICKINGER, VMD, PhD and GEORGE MIKHAIL, MD, FACOG

From the Endocrine Section, Department of Obstetrics and Gynecology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania

Abstract

During a 6-month course of treatment of endometriosis with Danazol®, a synthetic derivative of 17a-ethinyl testosterone, the following hormonal changes were found. Plasma LH remained essentially unchanged but FSH conceutration was consistently in the low normal range. Plasma estradiol, especially after the fourth week of therapy, dropped to levels that did not exceed 30 pg/ml throughout the 6-month period of therapy. Plasma progesterone concentration was consistent with follicular phase levels. In the months after discontinuation of Danazol, all hormone parameters were strongly suggestive of normal ovulatory cycles. Danazol did not displace estradiol bound by endometrial cytosol.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1975 by the American College of Obstetricians and Gynecologists.